



IDEX Biometrics ASA

Q2 2026 Results & Business Update

Oslo, August 2026

IDEX BIOMETRICS ASA

Second-Quarter 2026

Oslo, 19 August 2026

IDEX Biometrics ASA (Euronext Oslo Børs: IDEX) ended the second quarter of 2026 with an order backlog of NOK 23.7 million, all committed for delivery in the second half of 2026. The active pilot base has tripled to 23 pilots signed or live as of August, up from seven at the end of May.

The first half of 2026 was about building the commercial engine: signing pilots, expanding the channel partner network, and completing the certifications required by enterprise and public-sector buyers. While we will continue to add to that funnel, the second half is also about conversion. The Company expects a step-up in order intake and revenue as pilots convert into firm orders from Q3 and as the current backlog is delivered. Revenue for the third quarter is expected to exceed NOK 8.5 million, of which approximately NOK 4.5 million has been shipped as of the date of this report.

BUSINESS HIGHLIGHTS Q2 2026 AND TO DATE

- **Active pilot base tripled to 23.** IDEX has 23 customer pilots signed or live as of August 2026, up from seven at the end of May. 11 are live and 12 are signed but not yet live, of which 21 are within Access and 2 within Pay. One pilot within Pay was converted during Q2 and no pilots have been discontinued or lost to date. A further 5 pilots are in the near-term pipeline with scope being agreed. Management estimates combined initial purchase-order value of more than NOK 20 million across the current pilot base.
- **Four purchase orders received in Q2**, across both Access and Pay, representing order intake of NOK 1.9 million in the quarter. The largest were an order of approximately NOK 0.7 million from an existing Access customer for a combined digital and physical access card. Within Pay, one order came from a card manufacturer serving an Indian bank, a market in which we are currently experiencing traction.
- **Channel partner network expanded to 25 partners** from nine at the end of May, comprising distributors, resellers and technology partners. The network broadens geographic reach and go-to-market coverage and strengthens positioning for larger projects and public-sector tenders. The Company's distribution agreement with Infinigate has been expanded from Norway to a pan-European arrangement, with roadshow with key accounts underway.
- **FIDO Authenticator Certification Level 2 achieved**, broadening reach to high-security enterprise and public-sector customers.

CEO COMMENT

"The last couple of months is when our commercial model came together. We tripled the pilot base from 7 to 23 and expanded the partner network from 9 to 25. The funnel we have spent the first half building is now in place, and none of it has fallen away.

From here the task is conversion. We expect a step-up in order intake and revenue going forward as pilots convert and as the current backlog is delivered, and we have already shipped approximately NOK 4.5 million in the quarter to date. Beyond that, the 25 partners we have signed are only now beginning to sell. Almost all of the 23 pilots to date came from our own direct effort; the partner network brings established customer bases and local credibility that we cannot replicate ourselves, and that is where scale comes from.

We are also encouraged by the traction in Pay, where one pilot converted into a purchase order during the quarter, supporting an Indian bank launch in September, with two further banks in pilot phase and another in the pipeline”

— Kjell-Arne Besseberg, CEO, IDEX Biometrics ASA

FINANCIAL REVIEW

The table below summarises the Company's key financial and operational figures for the quarter.

NOK million unless stated	Q2 2026	Q1 2026	Q2 2025
Order backlog (end of period)	23.7	23.4	n.a.
Order intake	1.9	19.2	n.a.
Total revenue	1.6	0.9	0.8
Gross margin	19%	15%	28%
Operating expenses excl. SBC	20.5	19.0	32.0
Adjusted EBITDA	(20.2)	(18.9)	(31.7)
Share-based compensation (SBC)	1.7	6.2	(1.8)
Net financial items, gain / (loss)	13.2	(13.9)	10.0
Net result for the period	(9.0)	(39.4)	(21.0)
Operational cash flow	(45.2)	(9.7)	(15.1)
Cash and cash equivalents (end of period)	28.5	1.4	10.0
Full-time equivalents (end of period)	28	25	39

Adjusted EBITDA is defined as EBITDA excluding share-based compensation. Figures in parentheses are negative. Reported in NOK following the change of functional currency in the fourth quarter of 2025. First-quarter 2026 figures have been restated — see “Restatement of first-quarter 2026 revenue” below.

Restatement of first-quarter 2026 revenue

Revenue reported for the first quarter of 2026 has been reduced from NOK 1.8 million to NOK 0.9 million. The adjustment relates to a duplicate recording of a customer invoice in March 2026. The duplicate entry was identified shortly thereafter; however, the correction was recorded in April 2026 instead of being reflected in the March accounting records. The correction reduces first-quarter gross margin from 58% to 15%, adjusted EBITDA from negative NOK 18.1 million to negative NOK 18.9 million, and the net result for the period from negative NOK 38.5 million to negative NOK 39.4 million. The error was isolated to a single invoice and no other reporting period is affected.

Order intake and backlog

Order intake in the second quarter was NOK 1.9 million from four purchase orders, broadly in line with the NOK 2.1 million recorded in the first quarter excluding the one-off ID Centric purchase order. Order backlog was NOK 23.7 million at 30 June 2026, against NOK 23.4 million at 31 March 2026 and NOK 6.0 million at the end of 2025. The full backlog is committed for delivery during the

second half of 2026. Conversion of the pilot base into firm orders is expected from the third quarter.

Revenue

Total revenue for the second quarter of 2026 was NOK 1.6 million, compared with NOK 0.9 million in the restated first quarter of 2026 and NOK 0.8 million in the second quarter of 2025. The increase reflects higher shipments of upgraded IDEX products to existing and new customers. Quarterly revenue continues to depend on the timing of shipment completion, and deliveries against the backlog last quarter was as communicated weighted to the second half of the year.

Gross margin

Gross margin was 19% in the second quarter, up from 15% in the restated first quarter and down from 28% in the second quarter of 2025. As indicated in the first-quarter update, margin in the period was held back by partnership pricing on the initial ID Centric order, on which margins are thin, and this is expected to continue to affect the third quarter. Over time the Company expects gross margin to strengthen as the sales mix shifts towards complete Access Control solutions, which carry meaningfully higher margins than sensor sales alone, and as new orders are priced on full commercial terms.

Operating expenses

Operating expenses excluding share-based compensation were NOK 20.5 million, up 8% from NOK 19.0 million in the first quarter and down approximately 36% from NOK 32.0 million in the second quarter of 2025. The sequential increase reflects the addition of commercial capacity flagged in the first-quarter update, partly offset by continued cost optimisation elsewhere. Share-based compensation expense was NOK 1.7 million, a non-cash item reflecting the long-term incentive plan and share-price movement in the period; it is excluded from adjusted EBITDA to show the underlying operating result.

Adjusted EBITDA

Adjusted EBITDA was negative NOK 20.2 million, compared with negative NOK 18.9 million in the restated first quarter and negative NOK 31.7 million in the second quarter of 2025, an improvement of approximately 36% year on year. With the core cost base established, the Company expects incremental revenue to contribute to earnings at a high margin as volumes scale.

Net financial items

Net financial items were a gain of NOK 13.2 million, compared with a loss of NOK 13.9 million in the first quarter. The gain is predominantly non-cash and relates to the derecognition of the Heights loan on repayment, and was flagged in the first-quarter update. The net result for the period of negative NOK 9.0 million therefore includes this NOK 13.2 million non-cash gain; excluding it, the underlying net loss for the quarter was approximately NOK 22 million.

Cash flow and balance sheet

Cash and cash equivalents were NOK 28.5 million at 30 June 2026, against NOK 1.4 million at 31 March 2026. The movement comprises net equity proceeds of NOK 95.6 million, less NOK 28.6 million of debt repayment, including a loan provided by the former CEO Anders Storbråten, NOK 20.2 million of adjusted EBITDA, NOK 6.8 million of working-capital investment against backlog and pipeline, and NOK 12.9 million in settlement of payables that had been deferred during the first-quarter liquidity constraint. Following these transactions the Company has no interest-bearing debt.

The NOK 23.7 million backlog is scheduled for delivery in the second half against inventory that has already been manufactured, so conversion of that backlog into cash carries limited incremental cost.

OUTLOOK

Financial outlook

- **Step-up in orders and revenue from the third quarter.** The Company expects order intake and revenue to step up materially in the second half of 2026 as the current pilot base converts into firm orders and as backlog is delivered.
- **Third-quarter revenue expected to exceed NOK 8.5 million**, of which approximately NOK 4.5 million has been shipped as of the date of this update. Revenue recognition reflect shipment completion.
- **Backlog of NOK 23.7 million committed for second-half delivery**, with new orders expected to add to second-half revenue.
- **Operating costs are expected to increase in the third quarter** as the Company increases sales and marketing efforts where it sees high return.
- **Balance sheet.** The Company has no interest-bearing debt, and the backlog is scheduled for delivery against inventory already manufactured.

Operational and commercial outlook

- **Pilot conversions expected from the third quarter**, as previously communicated. Conversion is expected to take two to four months for SMB and enterprise customers and longer in the public sector, where mandatory tender processes can apply.
- **The funnel continues to refill.** New pilots are being signed alongside conversions, with five pilots in the near-term pipeline. As live references accumulate, the Company expects a growing share of customers to move directly from scoping to order without a pilot phase, shortening the sales cycle.
- **Scale from partner network.** Almost all pilots signed to date originated from IDEX's own direct sales effort. The 25 partners signed this year bring established customer bases, local credibility and distribution reach.
- **Public-sector tenders.** Several Norwegian public-sector tenders for identity and access management solutions are expected during the second half, and IDEX is working with partners on these. Public-sector awards can be larger in size and carry strong reference value for subsequent enterprise rollout.
- **IDEX Pay.** One pilot converted into a purchase order during the second quarter, supporting an Indian bank launch in September. Two further banks are in pilot phase and one more is in the pipeline.
- **Positive market momentum.** Demand for hardware-rooted authentication continues to be supported by the increase in AI-enabled attacks on software-based security, and by the shift of NIS2 and DORA from guidance into active enforcement across the EU. Both point enterprise and public-sector buyers towards phishing-resistant, hardware-bound authentication of the kind IDEX supplies.

GOING CONCERN

As of June 30, 2026, the Group held cash and cash equivalents of NOK 28.5 million and net equity of NOK 80.0 million. During the first six months of 2026, the Company completed equity financings raising aggregate gross proceeds of approximately NOK 110 million and repaid its convertible loan in full.

Management has prepared cash flow forecasts based on expected sales, available inventory resources and the Group's operating plans. While future cash flows remain dependent on the timing of customer deployments and expected sales development, the Board considers the Group's current funding position sufficient to support planned operations.

The Board has concluded that the interim financial statements have been prepared on a going concern basis. Further information is provided in Note 2

August 19, 2026

The Board of Directors of IDEX Biometrics ASA

Disclaimer

This Document (which may be a presentation, video, brochure or other material) includes and may be based on forward-looking information and statements that are subject to unknown risks and uncertainties that could cause actual results to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. The content of this Document is based on current management expectations, estimates and projections about global economic conditions, including the economic conditions of the regions and industries that are major markets for IDEX Biometrics ASA and its subsidiaries and affiliates. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates", "anticipates", "intends", "goals", "targets", "strategy" or similar expressions, if not part of what could clearly be characterised as a demonstration case, although not all forward-looking statements contain such terms. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Important factors that could cause actual results to differ materially from those expectations include, among others, changes in economic and market conditions in the geographic areas and industries that are or will be major markets for IDEX Biometrics ASA, the pace of market adoption of biometric solutions, the timing and volume of customer orders and programme roll-outs, the performance of partners, distributors and the supply chain, technological development and competition, changes in regulatory and trade conditions, and the Company's ability to obtain financing on acceptable terms. Although IDEX Biometrics ASA believes that its expectations and the Document are based upon reasonable assumptions, it can give no guarantee or assurance that those expectations will be achieved, or that future results or events will be consistent with any such opinions, forecasts or estimates. IDEX Biometrics ASA does not guarantee the accuracy, reliability or completeness of the Document, neither expressed nor implied, and no reliance should be placed on it. Except as required by applicable securities laws, we undertake no obligation to update or revise these statements based on new information, future developments or otherwise. IDEX Biometrics ASA (including its directors, officers and employees) assumes no liability related to the use of this Document or its contents. IDEX Biometrics ASA consists of several legally independent entities, constituting their own separate identities. IDEX Biometrics is used as the common brand or trademark for these entities. In this Document we may sometimes use "IDEX", "IDEX Biometrics", "the Company", "we" or "us" when we refer to IDEX Biometrics ASA companies in general or where no useful purpose is served by identifying any individual IDEX company.

CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED)

CONSOLIDATED STATEMENTS OF PROFIT AND LOSS

Amounts in NOK 1,000s	Note	Quarters		First half		Full year
		Q2 2026	Q2 2025	2026	2025	2025
Operating revenue						
Product revenue	4	1 441	828	2 324	1 682	2 345
Service and other revenue	4	193	-	193	251	242
Total revenue		1 634	828	2 516	1 933	2 588
Operating expenses						
Cost of materials, net of inventory change		1 318	577	2 065	1 496	6 223
Compensation and benefits	5	7 746	6 897	19 601	16 397	26 812
Research and development	6	2 216	5 388	5 151	11 057	14 942
Other operating expenses	7	12 219	17 355	22 687	34 079	58 686
Amortization, depreciation and impairment	8	352	1 432	704	2 907	4 848
Total operating expenses		23 851	31 650	50 208	65 936	111 512
Loss from operations		(22 218)	(30 823)	(47 692)	(64 003)	(108 924)
Other financial items, net	9	13 224	9 974	(698)	(1 013)	4 958
Profit (loss) before tax		(8 993)	(20 848)	(48 390)	(65 016)	(103 966)
Income tax benefit (expense)	10		460		433	419
Net profit (loss) for the period		(8 993)	(20 389)	(48 390)	(64 583)	(103 547)
Profit (loss) per share, basic and diluted	11	(0.12)	(0.68)	(0.71)	(3.37)	(2.65)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Amounts in NOK 1,000s	Quarters		First half		Full year
	Q2 2026	Q2 2025	2026	2025	2025
Net profit (loss) for the period	(8 993)	(64 583)	(48 390)	(64 583)	(103 547)
Foreign currency translation adjustment	(27)	(841)	(47)	(1 591)	(24)
Total comprehensive income (loss) for the period, net of tax	(9 020)	(66 175)	(48 437)	(66 175)	(103 571)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Amounts in NOK 1,000s	Note	June 30, 2026	June 30, 2025	December 31, 2025
Assets				
Non-current assets				
Goodwill		-	-	-
Intangible assets		4 356	5 262	4 780
Total intangible assets		4 356	5 262	4 780
Property, plant and equipment		244	804	423
Right-of-use assets		-	1 283	91
Non-current receivables		553	664	571
Total non-current assets		5 153	8 013	5 865
Current assets				
Prepaid expenses		2 419	6 186	2 935
Inventory	12	61 334	56 027	57 268
Accounts receivable, trade		287	847	517
Accounts receivable, other		3 662	4 799	3 183
Cash and cash equivalents		28 478	10 046	7 209
Total current assets		96 179	77 905	71 112
Total assets		101 333	85 918	76 977
Equity and liabilities				
Equity				
Share capital		77 309	47 364	62 601
Share premium		116 209	10 216	26 696
Share-based payment reserve		7 679	303	633
Foreign currency translation effects		(47)	-	(24)
Capital reduction reserves		-	-	-
Other equity (accumulated losses)		(121 136)	(48 598)	(75 176)
Total equity		80 014	9 286	14 731
Non-current liabilities				
Non-current non-interest-bearing loans		-	16 202	7 698
Other non-current financial liabilities		-	13 918	9 645
Non-current lease liabilities		-	0	0
Total non-current liabilities		-	30 120	17 343
Current liabilities				
Accounts payable		8 915	16 340	11 676
Current lease liabilities		-	2 133	844
Public duties payable		1 497	1 725	664
Interest-bearing loans		-	-	-
Other current financial liabilities		-	5 487	10 955
Other current liabilities		10 906	20 827	20 764
Total current liabilities		21 319	46 512	44 903
Total liabilities		21 319	76 632	62 246
Total equity and liabilities		101 333	85 918	76 977

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Note	Share capital	Share premium	Share-based payment reserve	Foreign currency translation effects	Capital reduction reserve	Other equity (accumulated losses)	Total equity
Balance at January 1, 2026		62 601	26 696	633	(24)	-	(75 176)	14 731
Share capital reduction	4,6,11	-	-	-	-	-	-	-
Share issuance	11	14 608	89 283	-	-	-	-	103 891
Share-based compensation	4,6,11	100	230	7 046	-	-	-	7 376
Loss for the period		-	-	-	-	-	(48 390)	(48 390)
Foreign currency translation effects		-	-	-	-	-	2 430	2 430
Other comprehensive income		-	-	-	(23)	-	-	(23)
Balance at June 30, 2026		77 309	116 209	7 679	(47)	-	(121 136)	80 014
Balance at January 1, 2025		124 737	28 305	208 687	(45 076)	3 635 233	(3 889 475)	62 412
Share capital reduction		(116 423)	(14 392)	(186 079)	-	(3 635 233)	3 952 128	-
Share issuance	11	36 003	(3 697)	-	-	-	-	32 306
Share-based compensation	4,6,11	3 048	-	(22 305)	-	-	-	(19 257)
Loss for the period		-	-	-	-	-	(66 175)	(66 175)
Foreign currency translation effects		-	-	-	45 076	-	(45 076)	-
Other comprehensive income		-	-	-	(1 591)	-	-	(1 591)
Balance at June 30, 2025		47 364	10 216	303	(1 591)	-	(47 006)	9 286
Balance at January 1, 2025		124 737	28 305	208 687	(45 076)	3 635 233	(3 889 475)	62 412
Share capital reduction		(116 423)	(14 392)	(186 079)	-	(3 635 233)	3 952 128	-
Share issuance	11	51 239	12 783	-	-	-	-	64 022
Share-based compensation	4,6,11	3 048	-	(21 975)	-	-	-	(18 927)
Loss for the period		-	-	-	-	-	(103 547)	(101 219)
Foreign currency translation effects		-	-	-	45 076	-	(34 281)	8 466
Other comprehensive income		-	-	-	(24)	-	-	(24)
Balance at December 31, 2025		62 601	26 696	633	(24)	-	(75 176)	14 731

CONSOLIDATED STATEMENTS OF CASH FLOWS

		Quarters		First half		Full year
	Note	Q2 2026	Q2 2025	2026	2025	2025
Profit (loss) before tax		(8 993)	(20 848)	(48 390)	(65 016)	(103 966)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>						
Amortization, depreciation and impairment expense	8	352	1 432	704	2 907	4 848
Share-based compensation expense	5	1 683	(1 685)	7 839	(3 420)	(4 732)
(Gain) loss on modification of financial liabilities, net		(12 744)	-	3 284	40 082	27 445
Value change convertible loan and warrants		(888)	(9 383)	(9 645)	(42 431)	(40 034)
Other financial items		580	1 227	7 260	4 068	-
<i>Other operating cash flows:</i>						
(Increase) decrease in inventories		202	(374)	(4 066)	(1)	(1 345)
(Increase) decrease in accounts receivables		(747)	172	(249)	(540)	(212)
Increase (decrease) in accounts payable		(11 552)	6 745	(2 761)	6 791	2 167
(Increase) decrease in other working capital items		(12 913)	7 383	(9 351)	12 327	26 522
			-		-	-
Interest paid		(190)	(34)	(224)	(81)	-
Change in income taxes		-	312	-	287	286
Net cash flow used in operating activities		(45 210)	(15 053)	(55 599)	(45 027)	(89 021)
Investing activities						
(Purchases) sales of property, plant and equipment	8	0	-	(67)	-	(443)
Change in non-current receivables		18	(40)	18	(40)	-
Payments on non-current receivables		(26)	-	-	-	-
Interest received	9	17	35	23	110	214
Net cash flow used in investing activities		9	(6)	(26)	70	(229)
Financing activities						
Net proceeds from issuance of shares		94 581	34 159	98 893	33 709	76 718
Proceeds from borrowings	14	-	(19 122)	0	0	0
Repayments of borrowings	14	(22 000)	-	(22 000)	-	-
Paid, not registered capital		-	-	-	-	-
Payments on lease liabilities	8	-	(912)	-	(1 848)	(3 120)
Payment related to a financed asset purchase		-	-	-	-	-
Change in non-current payables		(18)	-	(0)	0	-
Net cash flow from financing activities		72 563	14 125	76 893	31 860	73 598
Net change in cash and cash equivalents		27 362	(934)	21 268	(13 097)	(15 652)
Effect of foreign exchange rate changes		54	273	2	317	35
Opening cash and cash equivalents balance		1 062	10 708	7 209	22 826	22 826
Cash and cash equivalents at period end		28 478	10 047	28 478	10 046	7 208

NOTES TO THE CONSOLIDATED INTERIM NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1 The company and its business

IDEX Biometrics specializes in the design, development, and sale of fingerprint authentication solutions. The Company's fingerprint authentication solutions are used primarily in contactless smart cards, including financial payment cards, access control cards, and card-based devices for the storage of digital currencies. The Company is a public limited liability company incorporated and domiciled in Norway. The address of the head office is Henrik Ibsens gate 90, NO-0255 Oslo, Norway. There is one class of shares, and all shares have equal rights. The Company's shares are listed on Euronext Oslo Børs, the stock exchange in Oslo, Norway, under the ticker IDEX.

The technical development and supply chain activities are performed at the subsidiary in the United Kingdom.

2 Basis of preparation and accounting policies

These consolidated interim financial statements for the six-month period ended June 30, 2026 have been prepared in accordance with IAS 34 Interim Financial Reporting and have not been audited. The interim financial statements should be read in conjunction with the audited annual financial statements for the year ended December 31, 2025, which were prepared in accordance with IFRS Accounting Standards as adopted by the EU. The accounting policies applied in this interim report are consistent with those applied in the annual financial statements for 2025, except for the change in presentation currency. Effective from January 1, 2026, the company changed its presentation currency from USD to NOK. Comparative figures have been restated to reflect the new presentation currency and ensure comparability between periods. Amounts presented may include rounding differences.

IDEX Biometrics operates in one reporting segment: fingerprint imaging and recognition technology.

The condensed consolidated interim financial statements have been prepared on the basis of the going concern assumption.

Management has assessed the Group's ability to continue operations for at least 12 months from the date of approval of these interim financial statements.

As of June 30, 2026, the Group held cash and cash equivalents of NOK 28.5 million, net equity amounted to NOK 80.0 million and balance sheet solvency, defined as cash plus current receivables less current liabilities, was positive NOK 11.1 million.

During the first six months of 2026, the Company completed equity financings raising aggregate gross proceeds of approximately NOK 110 million. In addition, the Company's convertible loan was repaid in full during May 2026.

Management has prepared cash flow forecasts covering the assessment period. The forecasts are based on expected sales, available inventory resources and the Group's operating plans.

The Group's future liquidity remains dependent on the timing and extent of expected revenues and customer commercialization programs. Delays in forecast sales, customer deployments or other commercial activities could negatively impact the Group's liquidity position and may require management to implement mitigating actions.

Based on the Group's current liquidity position, forecast cash flows and available mitigating actions, the Board has on balance concluded that the going concern basis of preparation remains appropriate.

Accordingly, the interim financial statements have been prepared on a going concern basis.

3 Principal risks and uncertainties

It is the duty of the Board of Directors to present the principal risks facing the Company in the conduct of its business. The Company's primary risk is business risk, broadly defined as the risk to its ability to generate revenue and earn profit.

Business risk

Future revenue generation depends on several key factors:

- *The Company's ability to market and profitably deliver its products on a sustained basis*
- *The ability to raise sufficient capital to pursue strategic initiatives*
- *The ability to legally protect intellectual property rights*
- *The ability to scale operations efficiently*
- *The ability to retain and attract qualified employees*
- *The pace of development in the market for biometric payment and access cards, which remains in an early stage*

For further information on the Company's ability to continue as a going concern, see [Note 2 – Basis of Preparation and Accounting Policies].

Financial and liquidity risk

The Company's assets primarily consist of cash, working capital, and intangible assets. Liquidity is maintained by investing available funds in readily accessible, floating-interest rate bank accounts.

The Company is exposed to currency exchange rate fluctuations, which it manages by maintaining an appropriate mix of cash deposits in the currencies used in its operations. The Company does not engage in active hedging strategies.

Credit risk

Accounts receivables are subject to credit risk, which is not insured. Receivables are carried at original value, less specific reserves for estimated potential losses.

Inventory risk

Inventory is valued at the lower of cost or net realizable value, with reserves applied for aging and obsolescence. Inventory items are largely custom designed for IDEX and are substantially higher than short-term customer demand, creating a risk of technical or market obsolescence before sale.

Financing risk

The Company's convertible debt was fully repaid on 7 May 2026. As a result, the liquidity, foreign exchange and fair value risks previously associated with the convertible debt and its embedded derivative no longer exist at the reporting date. The repayment has reduced the Company's overall financial risk profile and eliminated future earnings volatility related to remeasurement of the embedded derivative.

4 Revenue from contracts with customers

Product-related revenue is recognized upon shipment, primarily on ex-works basis. Service revenue is recognized by customer acceptance of delivery.

As of June 30, 2026, the Company had contract liabilities of approximately NOK 1.0 million relating to advance payments received from customers for future product deliveries. There were no contract assets or contract liabilities as of December 31, 2025.

IDEX Biometrics categorizes customers by geographic region by the addresses to which IDEX Biometrics invoices its products or services. The Company's products and service revenue by geographic region is as follows:

Amounts in NOK 1,000	Quarters		First half		Full year
	Q2 2026	Q2 2025	2026	2025	2025
EMEA	3	471	3	616	666
Americas	540	280	540	280	561
Asia-Pacific	899	19	1 781	728	1 118
Product revenue	1 441	770	2 324	1 624	2 345
EMEA	-	-	-	-	-
Americas	-	-	-	242	242
Asia-Pacific	193	-	193	-	-
Service and other revenue	193	-	193	242	242
Total revenue	1 634	770	2 516	1 867	2 587

5 Compensation and benefits

Amounts in NOK 1,000	Quarters		First half		Full year
	Q2 2026	Q2 2025	2026	2025	2025
Salary, payroll tax, benefits, other	6 064	7 918	11 762	19 254	31 594
Share-based compensation	1 683	(1 584)	7 839	(3 420)	(4 782)
Compensation and benefits	7 746	6 334	19 601	15 834	26 812

Compensation and benefits expenses consist of costs for direct employees and board members of the Company. Compensation of individual contractors is reported as Research and development expenses or Other operating expenses, as applicable, based on the roles assigned to the individuals.

The cost of share-based remuneration is recognized in accordance with IFRS 2. See note 12, Shares, warrants and incentive subscription rights.

Share-based compensation expense increased significantly compared with the corresponding period in 2025. The prior-year period included reversals of previously recognized costs related to unvested subscription rights following employee departures, whereas the current period includes expense recognition from the incentive subscription rights granted in February 2026 as well as continuing vesting of outstanding awards.

The table below sets forth the number of employees and individual contractors by their function measured in full-time equivalents (FTE). Certain individuals are contractors because they work in countries in which the Company does not have a business presence.

Full-time equivalents (FTEs) by function	June 30, 2026		June 30, 2025		December 31, 2025	
	Employ-ees	Contrac-tors	Employ-ees	Contrac-tors	Employ-ees	Contrac-tors
Research and development	9	3	16	4	11	3
Marketing and sales	4	3	3	4	1	2
General and administrative	3	1	5	1	3	1
Supply chain and distribution	4	1	6	-	4	1
Total	20	8	30	9	19	7

6 Research and development expenses

Research costs are expensed when incurred. Development costs are expensed unless they qualify for capitalization. The Company's patents and other intellectual property rights created are capitalized and recorded on the Statement of financial position only if they satisfy the criteria for capitalization. The Company has not capitalized development costs in any of the periods presented. Development costs related to the creation of intellectual property have been expensed when incurred.

Amounts in NOK 1,000	Quarters		First half		Full year
	Q2 2026	Q2 2025	2026	2025	2025
Gross R&D expenses	2 268	4 489	5 152	10 157	15 879
Government grants credited to cost	(52)	520	(1)	520	(937)
Net R&D expenses	2 216	5 009	5 151	10 678	14 942

Government support is recognized when it is probable the Company will qualify and receive support, and the amount can be measured reliably. Norwegian SkatteFUNN grants are recorded in the fourth quarter and the UK SME R&D tax relief is normally recorded at year end. In the second quarter of 2026, adjustments to prior years' government grants represented net expense.

7 Related party transactions

Anders Storbråten served as Chief Executive Officer and Chief Financial Officer until 29 May 2026. His services were provided through Ludvig & Solan AG. Additional consulting management services were provided through Pinchcliff AS, a company also controlled by Mr. Storbråten.

Following the Annual General Meeting held on 29 May 2026, Mr. Storbråten was elected Chair of the Board. From June 2026, services provided by Mr. Storbråten have continued under an executive services agreement through Ludvig & Solan AG.

The Company expensed NOK 5.4 million during the first half of 2026 for services provided by Ludvig & Solan AG and Pinchcliff AS.

Morten Opstad served as Chair of the Board until the Annual General Meeting on 29 May 2026. During the first half of 2026, no executive services were invoiced by Ræder Bing Advokatfirma AS.

8 Non-current assets

Acquired intangible assets and intellectual property rights are capitalized at the time of acquisition and amortized over their estimated useful lives. The major intangible assets are amortized over approximately 9.5 years and 17 years from the date of acquisition, respectively. Internal development costs are expensed as incurred and are not capitalized.

Property, plant and equipment comprise scientific and test equipment, engineering tools, leasehold improvements, office equipment and furniture. These assets are depreciated on a straight-line basis over estimated useful lives ranging from three to seven years.

The Company has not made any changes to the valuation principles, depreciation methods or useful life assumptions applied in the 2025 annual financial statements.

The carrying amount of non-current assets was NOK 5.2 million on 30 June 2026, compared to NOK 5.9 million on 31 December 2025. Additions during the first half of 2026 amounted to NOK 0.1 million, while depreciation and amortization expense amounted to NOK 0.8 million.

9 Financial items

Amounts in NOK 1,000	Quarters		First half		Full year
	Q2 2026	Q2 2025	2026	2025	2025
Interest income	17	34	23	114	214
Interest (expenses)	(944)	(2 601)	(2 890)	(5.373)	(9.986)
Interest (expenses) on lease liabilities	-	(28)	-	(69)	(82)
Net interest (expenses)	(927)	(2 595)	(2 867)	(5.327)	(9 854)
Currency exchange gain (loss)	520	2 456	(1 797)	1 646	1.829
Gain (loss) on modification of financial liabilities, net	12.744	-	(3.284)	(40.009)	(32.252)
Change in fair value of financial instruments	888	9.876	9.645	(42.440)	(44.901)
Other financial income (expenses)	-	236	(2 395)	236	334
Other financial items, net	13 224	9.974	(698)	(1.013)	4 958

See note 14—*Financial instruments* regarding the gain or loss on financial instruments.

10 Income tax expense

The Company has significantly accumulated tax losses. No deferred tax asset associated with these accumulated tax losses has been recorded on the Statement of financial position, as there is not sufficient evidence that taxable profit will be generated, against which the unused tax losses could be applied. There are no restrictions as to how long tax losses may be carried forward in Norway.

11 Loss per share

	Quarters		First half		Full year
	Q2 2026	Q2 2025	2026	2025	2025
Profit (loss) attributable to the shareholders (NOK 1,000)	(8 993)	(20 389)	(48 390)	(64 583)	(103 547)
Weighted average basic number of shares	72 120 634	29 884 737	68 389 683	19 188 900	39 078 593
Weighted average diluted number of shares	72 120 634	29 884 737	68 389 683	19 188 900	39 078 593
Profit (loss) per share, basic and diluted (NOK)	(0.12)	(0.68)	(0.71)	(3.37)	(2.65)

A 100:1 share consolidation (reverse split) was completed at record date July 4, 2025. The per share calculations for all periods presented here are based on the new number of shares.

The profit or loss per share is calculated by dividing the profit (loss) for the period by the weighted average number of ordinary shares outstanding for the period. Loss per share is calculated per basic share (i.e., without consideration for the anti-dilutive effect of exercisable subscription rights or warrants).

12 Shares, warrants and incentive subscription rights

This note reports the number of shares registered as of 31 December 2025 and on earlier dates, including periods prior to the 100:1 share consolidation (reverse split) that became effective on 4 July 2025. All share and per share information presented has been adjusted to reflect the share consolidation. The subscription rights plans contain adjustment provisions under which the number of subscription rights and exercise prices are adjusted accordingly.

Number of financial instruments	Incentive subscription rights	Warrants	Shares
Balance at January 1, 2026	53 036		62 600 677
Jan 9: Conversion of loan			768 923
Jan 20: Share issue			1 642 363
Apr 29: Share issue			6 401 196
May 6: Share issue			100 000
May 7: Share issue			3 295 773
Jun 4: Share issue			2 500 000
Granted incentive subscription rights	4 650 000		
Expired/forfeited incentive subscription rights	(7 355)		
Balance at June 30, 2026	4 695 681		77 308 932
Balance at January 1, 2025	22 569 865	526 160 419	831 576 974
Mar 13: Warrants A exercise and expiry		(246 396 285)	17 258
Apr 11: Warrants B exercise and expiry		(246 430 801)	36 767
Apr 11: Share issue			3 000 000 000
Jun 4: Warrants May expiry		(33 333 333)	
Jun 6: Share issue			600 000 000
Jun 15: Share issue			299 381 600
Jun 23: Share issue			5 413 001
Employee Stock Purchase Plan			
Granted incentive subscription rights			
Expired/forfeited incentive subscription rights	(13 903 366)		
Balance at June 30, 2025	8 666 499		4 736 425 600
Balance at January 1, 2025	22 569 865	526 160 419	831 576 974
Mar 13: Warrants A exercise and expiry		(246 396 285)	17 258
Apr 11: Warrants B exercise and expiry		(246 430 801)	36 767
Apr 11: Share issue			3 000 000 000
Jun 4: Warrants May expiry		(33 333 333)	
Jun 6: Share issue			600 000 000
Jun 15: Share issue			299 381 600
Jun 23: Share issue			5 413 001
Jul 4: Before share consolidation 100:1	22 569 865		4 736 425 600
Jul 4: After share consolidation 100:1	225 699		47 364 256
Jul 21: Share issue			4 731 594
Aug 14: Share issue			4 359 315
Aug 14: Share issue			454 542
Dec 4: Share issue			5 690 970
Employee Stock Purchase Plan			
Granted incentive subscription rights			
Expired/forfeited incentive subscription rights	(172 663)		
Balance at December 31, 2025	53 036		62 600 677

On 11 March 2025, the Company entered into convertible loan agreements totaling NOK 30 million. Following approval by the EGM held on 11 April 2025, the loans were converted into equity and 3,000,000,000 new shares were issued on 28 April 2025.

The EGM held on April 11, 2025 resolved to reduce the share capital by reducing the par value of the shares from NOK 0.15 to NOK 0.01 per share. The reduction was allocated to partly cover accumulated losses and had no effect on total equity.

In June 2025, the Company completed a subsequent offering (repair issue) of 600,000,000 shares and a share issue of 299,381,600 shares to employees, contractors and directors. In addition, one board member elected to receive part of the Board remuneration for 2024–2025 in shares, resulting in the issuance of 5,413,001 shares. A 100:1 share consolidation (reverse split) became effective on 4 July 2025.

During the second half of 2025, the Company completed private placements totalling 14.8 million shares, raising gross proceeds of approximately NOK 52 million.

On 9 January 2026, a bondholder exercised its right to convert NOK 5.0 million of the convertible bond issued on 22 December 2023. The conversion resulted in the issuance of 768,923 new shares at a conversion price of NOK 6.50 per share.

On 20 January 2026, the Extraordinary General Meeting approved the second tranche of the private placement announced on 5 December 2025. The tranche comprised 1,642,363 new shares at a subscription price of NOK 3.00 per share.

On 28 April 2026, the Company completed a private placement of 9,696,969 new shares at a subscription price of NOK 8.25 per share, raising gross proceeds of NOK 80 million. The private placement was structured in two tranches and carried out pursuant to authorizations granted by Extraordinary General Meetings held on 20 January 2026 and 27 March 2026.

On 29 May 2026, the Company completed an additional private placement of 2,500,000 new shares at a subscription price of NOK 8.25 per share, raising gross proceeds of approximately NOK 20 million.

The Company maintains an incentive subscription rights program for employees and individual contractors. Unless otherwise resolved by the Board of Directors, 25% of each grant vests annually and expires on the fifth anniversary of the Annual General Meeting under which the grant was issued. The fair value of granted subscription rights is recognized over the vesting period in accordance with IFRS 2.

On 25 February 2026, the Company granted 4,650,000 incentive subscription rights under the Company's 2025 incentive subscription rights plan. Following grants and forfeitures during the period, 4,695,681 incentive subscription rights were outstanding at 30 June 2026.

No warrants were outstanding at 30 June 2026.

13 Inventory

Amounts in NOK 1,000	June 30, 2026			June 30, 2025			December 31, 2025		
	Cost	Reserves	Net	Cost	Reserves	Net	Cost	Reserves	Net
Raw Materials	24 397	(6 332)	18 065	39 808	-6 332	33 476	27 643	(6 332)	21 311
Work in progress	10 739	-	10 739	369	-	369	8 452	-	8 452
Finished Goods	39 318	(6 789)	32 529	31 322	(9 139)	22 183	34 219	(6 714)	27 505
Total Inventory	74 455	(13 121)	61 334	71 499	(15 471)	56 027	70 314	(13 046)	57 268

Inventories consist of raw materials, work in process, and finished goods. Materials and components purchased for use in research and development activities are expensed at the time of purchase and excluded from inventory. Inventory is recorded at the lower of cost and net realizable value, less impairment, if any.

On 11 March 2025, IDEX announced a strategic shift to focus on the access market while continuing to harvest opportunities in the payment market. As a result, certain materials and components held in inventory were assessed as less likely to be sold, and an inventory obsolescence provision was recognized.

On 30 June 2026, inventory amounted to NOK 61.3 million, net of inventory reserves of NOK 13.1 million.

Inventory levels increased during the first half of 2026, primarily reflecting inventory build-up to support anticipated customer deliveries.

14 Financial instruments

Convertible Bond

Amounts in NOK 1,000	Interest rate	Maturity	Recognized value on the balance sheet		
			June 30, 2026	June 30, 2025	December 31, 2025
Convertible bond	0 %	Semi-annual Amortization from June 28, 2026 to December 28, 2027			
Convertible debt			-	21 690	18 653
Embedded derivative			-	13 918	9 645
Total			-	35 607	28 298

On 9 January 2026, a bondholder exercised its right to convert NOK 5.0 million of the convertible bond issued on 22 December 2023. The conversion resulted in the issuance of 768,923 new shares at a conversion price of NOK 6.50 per share.

As part of the private placements completed during the first half of 2026, the Company reached an agreement with the holders of the outstanding convertible bond to fully and finally settle the remaining principal amount. The outstanding balance was redeemed through a cash payment of NOK 22 million, together with related legal expenses.

Following the settlement, no convertible bond debt or related embedded derivative remained outstanding on 30 June 2026.

In the second quarter of 2026, IDEX recognized net NOK 13.6 million in gain from change in fair value of financial instruments.

15 Legal proceedings

Former employee matter

On 2 October 2025, the Company was notified of legal proceedings by a former employee concerning termination terms.

Following further investigations and dialogue between Alta Consulting/Ms. Eklöf and the Company, the parties reached an amicable settlement. As the underlying conditions existed at the balance sheet date, the settlement constitutes an adjusting event under IAS 10.

As of 13 March 2026, the settlement resulted in total payments of EUR 280 thousand and NOK 500 thousand in legal costs. These amounts are consistent with the provision recognised at 31 December 2025, and no adjustment to the provision has been made.

Payment dispute

In January 2026, the Company received a payment reminder from Ræder Bing Advokatfirma AS. The Company disputes the invoiced amounts, asserting that certain services were rendered without a valid underlying agreement and that certain services were not ordered. Ræder Bing maintains that the invoices are valid.

On 29 June 2026, Ræder Bing filed a statement of claim with the Oslo District Court. The Company received the statement of claim on 6 August 2026. The matter remains unresolved.

The disputed amount was fully recognized in the Company's 2025 financial statements.

16 Events after the balance sheet date

No events occurred after June 30, 2026 that have had a material impact on the Company's financial position, results of operations, or cash flows.

RESPONSIBILITY STATEMENT

The Board of Directors and the Chief Executive Officer have today reviewed and approved the IDEX Biometrics ASA unaudited interim condensed consolidated financial statements as of June 30, 2026. To the best of our knowledge, we confirm the following:

- The interim condensed consolidated financial statements with notes for the first half of the calendar year 2026 have been prepared in accordance with IAS 34 Interim Financial Reporting and additional disclosure requirements as stated in the Norwegian Securities Trading Act section 5-6.
- The interim condensed consolidated financial statements for the first half calendar year of 2026 give a true and fair view of the Company's assets, liabilities, financial position, and results for the period viewed in their entirety.
- The report from the Board of Directors issued in concert with these condensed financial statements gives a true and fair view of the development, performance, and financial position of the Company, and a fair review of important events that have occurred during the first six months of the financial year and their impact on the interim condensed consolidated financial statements.
- A description of the principal risks and uncertainties for the remaining six months of the financial year have been disclosed in note 3 to the financial statements.
- Major related party transactions have been disclosed in note 7 to the financial statements.
- The report from the Board of Directors has been prepared in accordance with the Norwegian accounting act and generally accepted accounting practice in Norway.

August 19, 2026

The Board of Directors of IDEX Biometrics ASA

/s/ Anders Storbråten
Executive Chair

/s/ Annika Olsson
Board member

/s/ Adriana Saitta
Board member

/s/ Kjell-Arne Besseberg
CEO